GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

TECH · Sep 30, 2024

BIO-TECHNE Corp. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001558370-24-014439General Corporate

Debt relative to revenueRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.debt_to_revenue

103.64% · OPTIONAL · NOT_ENOUGH_HISTORY

Capex intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

3.17% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

22.07% · OPTIONAL · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

63.93% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

63.23% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

13.81% · CORE · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

3.52% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History11 statesHistory building

Dec 31, 20230/7 normalizedLevel 3 Mar 31, 20240/7 normalizedLevel 3 Jun 30, 20240/7 normalizedLevel 3 Sep 30, 20240/7 normalizedLevel 3 Dec 31, 20240/8 normalizedLevel 3 Mar 31, 20250/8 normalizedLevel 3 Jun 30, 20250/8 normalizedLevel 3 Sep 30, 20250/8 normalizedLevel 3 Dec 31, 20257/8 normalizedLevel 3 Mar 31, 20267/8 normalizedLevel 3 Jun 30, 20267/8 normalizedLevel 3

Period transition

What moved in the state?

Balance Sheet Leverage Increased

Previous: 27.52%
Current: 103.64%
Delta: 76.12%

Capex Intensity Decreased

Previous: 5.42%
Current: 3.17%
Delta: -2.26%

Cash Generation Decreased

Previous: 25.80%
Current: 22.07%
Delta: -3.72%

Inventory Pressure Increased

Previous: 15.51%
Current: 63.93%
Delta: 48.42%

Margin Decreased

Previous: 66.41%
Current: 63.23%
Delta: -3.18%

Profitability Decreased

Previous: 17.83%
Current: 13.81%
Delta: -4.02%

Sbc Intensity Increased

Previous: 3.28%
Current: 3.52%
Delta: 0.24%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · TECH Fundamental State →Has State · BIO-TECHNE Corp →Transitioned To · TECH Fundamental State →Transitioned To · TECH BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · TECH CAPEX_INTENSITY_DECREASED →Transitioned To · TECH CASH_GENERATION_DECREASED →Transitioned To · TECH INVENTORY_PRESSURE_INCREASED →Transitioned To · TECH MARGIN_DECREASED →Transitioned To · TECH PROFITABILITY_DECREASED →Transitioned To · TECH SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.